Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial. Επικοινωνία Submitted by Δημήτρης Σπάχος on Πέμ, 04/21/2016 - 11:16
